Psilocybin and LSD in the Treatment of Depression and Anxiety
2020 (English)Independent thesis Basic level (degree of Bachelor), 15 credits / 22,5 HE credits
Student thesis
Abstract [en]
Psychiatry is in a crisis. Mental health disorders are on the rise worldwide and there are currently not enough efficient treatment methods that would meet the patients’ needs. Hence, the societal and economic costs of mental health problems are enormous, as well as the suffering of individuals afflicted by mental health problems. Lysergic acid diethylamide (LSD) and psilocybin are substances that create an altered state of consciousness characterized by altered sensory perception and on some occasions, ego-dissolution, and mystical experiences. In recent studies, LSD and psilocybin have been shown to carry significant therapeutic potential in the treatment of depression and anxiety disorders in conjunction with psychotherapy. The therapeutic effects of LSD and psilocybin have also been shown to persist for between 3-12 months post-treatment. LSD and psilocybin, like other classical hallucinogens, increase serotonin availability, which has been suggested to attenuate symptoms of anxiety and depression. In addition, LSD and psilocybin alter the activity of the default mode network, which has been suggested to be overly active in depressed and anxious patients. This essay is a literature review of the neural mechanisms of LSD and psilocybin, their potential therapeutic effects in the treatment of depressive and anxiety disorders, and how insights about said neural mechanisms may be useful in understanding the possible application of psychedelics in the treatment of depressive and anxiety disorders. In sum, recent studies have provided converging and convincing evidence on therapeutic potential of LSD and psilocybin. Yet, few conclusions on the exact neural mechanisms of how LSD and psilocybin alleviate depressive and anxiety symptoms can be made. Although the future of this research field looks promising, archaic national- and international regulations continue to be a hindrance to research into psychedelic drugs. Yet, due to the psychiatric crisis and the promising results so far, more studies in this field are warranted.
Place, publisher, year, edition, pages
2020. , p. 40
Keywords [en]
LSD, psilocybin, cognitive neuroscience, psychedelic-assisted therapy, depression, anxiety, 5-HT2A, Default Mode Network
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:his:diva-18843OAI: oai:DiVA.org:his-18843DiVA, id: diva2:1454576
Subject / course
Cognitive Neuroscience
Educational program
Cognitive Neuroscience - Applied Positive Psychology
Supervisors
Examiners
2020-07-172020-07-172020-07-17Bibliographically approved